Deciphera Pharmaceuticals LLC (DCPH) Stock

DelistedNasdaq: DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.

25.59
Final close · Jun 10, 2024

DCPH is no longer traded. Deciphera Pharmaceuticals LLC was acquired by Ono Pharmaceutical on June 11, 2024.

Each DCPH share was exchanged for $25.60 in cash. Prices on this page are historical; the last trade was June 10, 2024 at $25.59.

Deciphera Pharmaceuticals LLC stock price history

Split-adjusted closes, 2017–2024

DCPH final trading statistics

Final close
$25.59
Final trading day
Jun 10, 2024
Market cap at delisting
$2.21B
Shares outstanding
86.48M
Final 52-week range
$9.90 – $25.61
Avg. volume (final 3 mo.)
1,822,166
All-time high (split-adj.)
$4937.50 · Dec 2016
All-time low (split-adj.)
$3.62 · Dec 2016
Return since IPO
-74.4%
Beta
0.18
Book value / share
$3.85
Price / book
6.65
Final 52 wk
9.9025.61

Deciphera Pharmaceuticals LLC earnings per share

Earnings per share

Deciphera Pharmaceuticals LLC revenue & net income

RevenueNet income

Deciphera Pharmaceuticals LLC annual financials

Fiscal yearRevenueNet incomeEPS
FY2023$163.36M-$194.9M-$2.29
FY2022$134.04M-$178.9M-$2.55
FY2021$96.15M-$296.8M-$5.15
FY2020$42.09M-$266.5M-$4.79
FY2019$25.00M-$191.5M-$4.40

Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.

About Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.

Deciphera Pharmaceuticals LLC stock FAQ

What happened to Deciphera Pharmaceuticals LLC stock?

Deciphera Pharmaceuticals LLC was acquired by Ono Pharmaceutical on June 11, 2024. Shareholders received $25.60 in cash for each share. DCPH stock stopped trading on the Nasdaq, with a final close of $25.59 on June 10, 2024.

What did Deciphera Pharmaceuticals LLC shareholders receive?

Each DCPH share was converted into $25.60 in cash. The deal was valued at about $2.4 billion.

Is DCPH stock still trading?

No. DCPH was delisted from the Nasdaq on June 11, 2024 and no longer trades on a U.S. exchange.

What was the last price of DCPH stock?

DCPH closed at $25.59 on its final trading day, June 10, 2024, for a market value of about $2.21B.

What were Deciphera Pharmaceuticals LLC's revenue and earnings in its last full fiscal year?

Deciphera Pharmaceuticals LLC reported revenue of $163.36M and net income of -$194.9M in fiscal 2023, its last full year as a public company.

When did Deciphera Pharmaceuticals LLC go public?

Deciphera Pharmaceuticals LLC stock began trading on September 28, 2017.

Drug Manufacturers - Specialty & Generic stocks to research

All Healthcare stocks →